FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(h).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Biller Scott				2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO					(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (check title) Other (specify)					
C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET				3. Date of Earliest Transaction (Month/Day/Year) 05/23/2018						X Officer (give title Other (specify below) Chief Scientific Officer					
(Street) CAMBR (City)		IA State)	02139 (Zip)		4. If Am 05/29/		ent, Date of	f Original Filed	I (Month/Day	r/Year)	6. Inc Line)	Form fil	oint/Group Filing ed by One Rep ed by More tha	orting Persor	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 5)			Securities Beneficia Owned Fo Reported Transacti	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of ndirect Beneficial Ownership Instr. 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	ate Execution Date,	Cod	4. Transaction Code (Instr. 8)		umber of ivative urities uired (A) bisposed D) (Instr. 3, Id 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Securiti Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock option (right to buy)	\$31.64	05/23/2018		M ⁽	1)		15,177 ⁽²⁾	(3)	03/04/2024	Common stock	15,177	\$0.00	14,862	D	

Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction.
- 3. This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ William Cook, as Attorney in Fact for Scott Biller

08/10/2018

** Signature of Reporting Person

Date

 $Reminder: \ Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.